Zevra Therapeutics Inc. (ZVRA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 45.7 (NEUTRAL RANGE)
Capital intensity & 0% operating margin leave 16 pts on the table
While ZVRA currently carries a cautious 40/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.18) and Max Pain ($10.88) forces dealer call-delta covering toward $15.79.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Zevra Therapeutics Inc. (ZVRA) advanced +0.49% to $10.36, trading at 33% of its 52-week range ($8.01 – $15.04). Stretched risk/reward at 7x P/E (-32% return on capital) under elevated 10-year interest-rate pressure.
BOSTON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases,
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ZVRA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ZVRA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Zevra Therapeutics Inc. (ZVRA) ranks #635 by composite RQD confidence (40/100, grade D-) and #417 by equity capitalization ($615.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ZVRA at 40/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZVRA
ACTIVE
Zevra Therapeutics Inc. | D- | 40/100 | 7.4x | — | -32.3% | +0.49% | $615.2M | Benchmark Subject |
| GERN Geron Corporation | D- | 37/100 | — | — | -20.2% | -2.30% | $607.9M | /gern-vs-zvra → |
| NVCT Nuvectis Pharma Inc. | D- | 43/100 | — | — | -35.0% | +1.14% | $605.6M | /nvct-vs-zvra → |
| IRWD Ironwood Pharmaceuticals Inc. (Class A) | C+ | 69/100 | 24.9x | — | 85.0% | +0.28% | $598.2M | /irwd-vs-zvra → |
| CRMD CorMedix Inc. | C | 62/100 | 3.7x | 88.5% | 45.5% | -6.83% | $595.5M | /crmd-vs-zvra → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $83.2M, operating cash flow of -$1.6M, and free cash flow of -$2.4M (+96.5% YoY). On the balance sheet, ZVRA closed FY2025 with $284.7M in total assets against $61.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $83.2M | -$1.6M | -$2.4M | $284.7M | $61.9M |
| FY2024 (FY) | 2024-12-31 | $0 | -$105.5M | -$69.7M | -$69.7M | $178.1M | $59.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$46.0M | -$33.5M | -$33.5M | — | — |
As of 2026-11-01, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $10.36 (+0.49% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #635 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (40/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, GERN (Geron Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and NVCT (Nuvectis Pharma Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).
Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $0 in revenue, $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ZVRA last traded at $10.36 (+0.49% on volume of 507,890 shares), positioning the stock -7.33% below its 50-day simple moving average ($11.18) and -3.63% below its 200-day simple moving average ($10.75). Across its 52-week range of $8.01 to $15.04, ZVRA sits at the 33.4% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($9.31 to $11.41).
Why ZVRA Stock advanced +0.49% Today — RQD Quant Desk Flash. Stretched risk/reward at 7x P/E (-32% return on capital) under elevated 10-year interest-rate pressure.